PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 05/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. KPTI, LTRN, KRON, XLO, AADI, PRLD, MRSN, AVTX, NRXP, and RNXTShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Karyopharm Therapeutics (KPTI), Lantern Pharma (LTRN), Kronos Bio (KRON), Xilio Therapeutics (XLO), Aadi Bioscience (AADI), Prelude Therapeutics (PRLD), Mersana Therapeutics (MRSN), Avalo Therapeutics (AVTX), NRx Pharmaceuticals (NRXP), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Karyopharm Therapeutics Lantern Pharma Kronos Bio Xilio Therapeutics Aadi Bioscience Prelude Therapeutics Mersana Therapeutics Avalo Therapeutics NRx Pharmaceuticals RenovoRx Karyopharm Therapeutics (NASDAQ:KPTI) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Do analysts rate KPTI or PHXM? Karyopharm Therapeutics currently has a consensus price target of $43.20, suggesting a potential upside of 819.15%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Karyopharm Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, KPTI or PHXM? Karyopharm Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Is KPTI or PHXM more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-52.62% N/A -39.58% PHAXIAM Therapeutics N/A N/A N/A Do institutionals & insiders have more ownership in KPTI or PHXM? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 3.0% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor KPTI or PHXM? Karyopharm Therapeutics received 544 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes54472.44% Underperform Votes20727.56% PHAXIAM TherapeuticsN/AN/A Which has stronger earnings and valuation, KPTI or PHXM? PHAXIAM Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$142.13M0.29-$143.10M-$13.26-0.35PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Does the media prefer KPTI or PHXM? In the previous week, Karyopharm Therapeutics had 9 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 9 mentions for Karyopharm Therapeutics and 0 mentions for PHAXIAM Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.37 beat PHAXIAM Therapeutics' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Karyopharm Therapeutics Neutral PHAXIAM Therapeutics Neutral SummaryKaryopharm Therapeutics beats PHAXIAM Therapeutics on 9 of the 14 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$129.28M$5.37B$8.38BDividend YieldN/A3.74%5.22%4.11%P/E RatioN/A3.4526.8419.71Price / Sales0.324,234.32392.34117.39Price / CashN/A13.1938.2534.62Price / Book0.3933.126.794.50Net Income-$240,000.00-$91.56M$3.23B$248.18M7 Day PerformanceN/A3.79%4.07%1.14%1 Month PerformanceN/A8.34%12.52%15.20%1 Year PerformanceN/A100.36%16.83%6.56% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049KPTIKaryopharm Therapeutics3.8392 of 5 stars$4.95+2.0%$43.20+773.6%-69.8%$42.25M$145.24M-4.83380Gap DownLTRNLantern Pharma3.0177 of 5 stars$3.90-3.9%$25.00+541.0%-40.2%$42.06MN/A-2.1920Earnings ReportAnalyst RevisionKRONKronos Bio2.5061 of 5 stars$0.70-4.1%$1.63+133.8%-35.1%$42.01M$9.19M-0.48100XLOXilio Therapeutics2.6401 of 5 stars$0.81-5.2%$4.00+396.3%-28.1%$41.73M$6.34M-0.4770AADIAadi Bioscience0.6711 of 5 stars$1.65-1.2%$1.67+1.0%-5.4%$40.75M$25.07M-0.7240PRLDPrelude Therapeutics3.085 of 5 stars$0.90+0.1%$4.00+342.5%-76.2%$39.82M$7M-0.51120Positive NewsGap UpMRSNMersana Therapeutics3.7947 of 5 stars$0.32-16.3%$3.67+1,053.0%-85.9%$39.76M$40.50M-0.52150Earnings ReportAnalyst RevisionGap DownAVTXAvalo Therapeutics3.4217 of 5 stars$3.64+1.0%$33.00+807.8%-63.1%$39.41M$441,000.000.0040Gap DownNRXPNRx Pharmaceuticals1.9267 of 5 stars$2.26-0.5%$28.50+1,162.2%-31.5%$38.76MN/A-1.052News CoverageEarnings ReportGap UpRNXTRenovoRx2.6686 of 5 stars$1.06+1.0%$7.00+560.4%-12.9%$38.01M$43,000.00-1.826Positive NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Karyopharm Therapeutics Competitors Lantern Pharma Competitors Kronos Bio Competitors Xilio Therapeutics Competitors Aadi Bioscience Competitors Prelude Therapeutics Competitors Mersana Therapeutics Competitors Avalo Therapeutics Competitors NRx Pharmaceuticals Competitors RenovoRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHXM Stock Free PHXM Stock Alerts